Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

HPLC Analysis of Procainamide-Labeled Cetuximab Glycans on BIOshell™ Glycan using HILIC-FLR

HPLC Analysis of Procainamide-Labeled Cetuximab Glycans on BIOshell™ Glycan using HILIC-FLR

Conditions

column BIOshell Glycan, 15 cm x 2.1 mm I.D., 2.7 µm particles (55094-U)
column temp. 58 C
mobile phase [A] 50 mM ammonium formate, pH 4.4 (50 mM ammonium hydroxide, adjusted to pH 4.4 with formic acid); [B] acetonitrile
gradient 75 to 59% B in 75 min
flow rate 0.3 ml/min
sample Cetuximab
injection 10 µl
detector FLR, ex 308 nm, em 359 nm

Description

Analysis Note Cetuximab is a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor. It is used to treat head and neck as well as colorectal cancers. The antibody is N-glycosylated both in the Fc and Fab regions, which have been shown to impact safety and quality of the drug. Thus, understanding glycosylation patterns is exceptionally important. As shown in this application report, the BIOshell Glycan column is able to elucidate the complex glycosylation of this biotherapeutic, allowing a better understanding of the drug’s efficacy.
Categories Analytical Chromatography, Carbohydrates
Featured Industry Life Science and Biopharma
Legal Information BIOshell is a trademark of Sigma-Aldrich Co. LLC
suitability application for HPLC

Materials

     
Related Links